Future Directions and Conclusion: Future work in dermatomyositis should center on precision medicine driven by myositis-specific autoantibodies: anti-MDA5 guiding early ILD-focused regimens (often including JAK inhibition), anti-TIF1-γ or anti-NXP2 prompting intensified, time-bound cancer screening, and anti-Mi-2 favoring skin-predominant steroid-sparing strategies. This evidence concerns the gene TRIM33 and interstitial lung disease.